Apeiron Therapeutics develops biomarker-driven small molecule therapies for cancer using structure-based, AI-driven drug design. The company focuses on creating targeted treatments for solid tumors with specific genetic deletions, addressing significant gaps in current cancer therapies.
Funding
$17.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
Many solid tumors have specific genetic deletions that are not effectively targeted by current cancer therapies, leading to unmet medical needs and suboptimal patient outcomes. The development of targeted treatments for these tumors is hindered by the complexity of drug discovery and the need for precise biomarker identification.
Solution
Apeiron Therapeutics develops biomarker-driven small molecule therapies for cancer, focusing on solid tumors with specific genetic deletions. The company leverages structure-based, AI-driven drug design to create targeted treatments. By integrating artificial intelligence with expertise in drug discovery, Apeiron aims to improve patient outcomes through a pipeline of best-in-class and first-in-class therapies that address significant gaps in current cancer treatments.
Target Audience
The primary target audience includes patients with solid tumors harboring specific genetic deletions, as well as oncologists and medical professionals seeking more effective and targeted cancer therapies.
Features
- Structure-based drug design for precise targeting of cancer cells
- AI-driven drug discovery to accelerate the identification of promising therapeutic candidates
- Focus on small molecule therapies for enhanced drug delivery and efficacy
- Development of biomarker-driven treatments to personalize cancer therapy
- Pipeline of targeted cancer treatments designed to address unmet medical needs
- Clinical-stage development with ongoing Phase 1a/b study of PRMT5 inhibitor GTA182 for MTAP-deleted solid tumors